786 A randomized, double blind, placebo controlled phase II trial to evaluate the safety and efficacy of recMAGE-A3 + AS15 antigen specific cancer immunotherapy in patients with MAGE-A3 positive muscle invasive bladder cancer after cystectomy: An initial report of the EAU Research Foundation randomized phase II clinical trial ‘Magnolia’
2014; Elsevier BV; Volume: 13; Issue: 1 Linguagem: Inglês
10.1016/s1569-9056(14)60774-0
ISSN1878-1500
AutoresPeter F.A. Mulders, Marc Colombel, Axel Heidenreich, Luis Martínez‐Piñeiro, Marek Babjuk, Igor A. Korneyev, C. Surcel, P. Yakovlev, Renzo Colombo, P. Radziszewski, J.A. Witjes, Robert‐Jan Schipper, Wim P.J. Witjes, Steering Committee Magnolia,
Tópico(s)Immunotherapy and Immune Responses
Referência(s)